The chin was already the product's established indication. Galderma says Restylane Shaype is approved for chin augmentation in Europe, Brazil, Canada and Thailand. Mexico adds a second indication in the same market, which matters more for a Mexican clinic than the headline does.
What changed
Galderma says the product is a firmer gel built to deliver a bone-mimicking effect. The release says the gel runs on the company's new NASHA HD technology and has the highest G' (its firmness measure) of the Restylane range. That is the number to bring to a supplier call. The release also says the gel is among the firmest HA fillers on the market from the leading brands, though it names no competitors.
The company also introduced a new, next-generation syringe. It says the syringe lets users work more precisely thanks to an ergonomic design and a revised syringe-needle connection. Galderma pairs the product with a training method it calls the Shayping Technique. That method uses the company's AART framework and the Facial Assessment Scale to guide how practitioners evaluate patients.
The clinical numbers, as Galderma reports them
The release cites a key 12-month chin study. In it, 83 percent of people showed improved structure and definition at three months, and 66 percent at 12 months. Galderma says 84 percent would agree to be treated again.
For the jawline, the company cites a study in which the product outperformed no treatment in restoring definition, with gains lasting up to two years. Seventy percent reported better overall satisfaction. A separate jawline study reports over 92 percent would recommend it to a friend.
These are sponsor-reported figures. The release gives no study size, no control design for the chin trial, and no dropout numbers. The 97 percent recommend-to-a-friend figure comes from a satisfaction survey, not an efficacy measure. Treat it as marketing until you see the protocol.
What it means for practices
Analysis: the jawline is the commercial reason for this release. Chin filler is crowded. A jawline claim with a defined scope gives a clinic a service to name on a menu and a reason to revisit patients who already had lower-face work. Galderma says the chin is the third most treated area among existing HA users, based on its own market research. That research is not described in the release, so ask for it before you build a campaign around it.
The release ties the product to medication-driven weight loss and menopause. Those are real demand drivers in Mexico and elsewhere, but the release offers no data specific to either group. It is positioning, not evidence.
What owners can do
Ask your distributor for the Mexican registration documents, the approved jawline wording and the labeled use. The release says "approved indications vary by market," so do not assume the Mexican label carries over to the chin label in your country.
Check whether the Shayping Technique training is available in your market and who delivers it. Galderma describes it as a way to standardize assessment, so clinics that skip it will have no record of why they treated what they treated.
Ask about the new syringe. Test it on a non-patient session before it goes into a booked case. The release describes a changed connection, and you will want to know how it handles against your current stock.
If you are outside Mexico, the approval does not reach you. Chin use under your local label is the only thing you can book now.
What we don't know yet
The release does not give the Mexican approval date, the registration number, the dosing or injection volumes, or the label's contraindications. It does not say whether the jawline indication is limited to a specific age group or patient profile. It also does not say when, or whether, other markets will file for the jawline. Galderma has not said what the product will cost in Mexico or whether it is already on shelves there.
Business information, not medical or legal advice. Verify regulatory status at FDA.gov.